Senhwa Biosciences, Inc.
Senhwa Biosciences, Inc., a drug development company, engages in the development of new drugs and targeted agents. The company develops CX-5461, a phase I, open-label, dose escalation, safety, pharmacokinetic, and pharmacodynamics study of intravenously administered CX-5461 in patients with advanced hematologic malignancies; CX-5461, which is in a phase I study for solid tumors; CX-5461 that is i… Read more
Senhwa Biosciences, Inc. (6492) - Net Assets
Latest net assets as of : NT$- TWD
Based on the latest financial reports, Senhwa Biosciences, Inc. (6492) has net assets worth NT$- TWD as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$-) and total liabilities (NT$-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Senhwa Biosciences, Inc. - Net Assets Trend (None–None)
This chart illustrates how Senhwa Biosciences, Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Senhwa Biosciences, Inc. (None–None)
The table below shows the annual net assets of Senhwa Biosciences, Inc. from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to Senhwa Biosciences, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
Senhwa Biosciences, Inc. Competitors by Market Cap
The table below lists competitors of Senhwa Biosciences, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CLEARVISE AG INH O.N.
F:ABO
|
$14.31K |
|
Nabors Energy Transition Corp. II Warrant
NASDAQ:NETDW
|
$14.32K |
|
PURPOSE MARIJ.OPP. TR.UTS
F:43V
|
$14.32K |
|
450940
KQ:450940
|
$14.32K |
|
Bich Chi Food Co
VN:BCF
|
$14.30K |
|
SYRAKUS HOLDING
BE:HZH
|
$14.29K |
|
Mobotix AG
F:MBQ
|
$14.29K |
|
Somero Enterprise Inc
LSE:SOM
|
$14.27K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Senhwa Biosciences, Inc.'s equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares Senhwa Biosciences, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently Senhwa Biosciences, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares Senhwa Biosciences, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Senhwa Biosciences, Inc. (6492) | NT$- | N/A | N/A | $14.31K |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |